Shopping Cart 0
Cart Subtotal
USD 0

Astellas Pharma Inc (4503) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company's product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc (4503)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 11

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

Astellas Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 31

Venture Financing 31

Coda Biotherapeutics Raises USD19 Million in Series A Financing 31

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 32

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 34

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 36

Oncorus Raises Additional USD4 Million in Series A Financing 38

Cleave Biosciences Raises USD37 Million in Series B Financing Round 39

Tizona Therapeutics Raises USD43 Million in Series B Financing 41

Tizona Therapeutics Secures USD27 Million in Series A Funding Round 43

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 44

Euroscreen Raises USD17.8 Million in Series B Financing Round 46

Quethera Raises Funds in Seed Financing Round 48

Ocata Therapeutics Secures USD6 Million from Silicon Valley Bank 49

Kanyos Bio Raises USD16 Million in Venture Financing 50

Potenza Therapeutics Raises USD38 Million in Series A Venture Financing 51

Crescendo Biologics Raises Funds through Venture Financing 52

Innocrin Pharma Raises Funds through Venture Financing 53

Viamet Pharma Raises USD60 Million in Series D Venture Financing 54

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 55

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 56

Crescendo Biologics Raises USD 28 Million In Series A Financing 58

Seldar Pharma Raises USD 13 Million In Venture Financing 60

Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 61

Universal Cells Raises USD0.06 Million in Venture Financing 62

Ganymed Pharma Raises USD 60.7 Million In Series E Financing 63

Mitokyne Raises USD 45 Million In Series A Financing 64

Effector Therapeutics Raises USD 45 Million In Series A Financing 65

Tacurion Pharma To Raise USD 15 Million In Venture Financing 67

Cleave Biosciences Raises USD 54 Million In Series A Financing 68

DecImmune Therapeutics Raises USD 2.2 Million In Financing Round 70

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 71

Euroscreen Raises USD 13 Million In Series A Financing 73

F2G Raises USD 30 Million In Venture Financing 74

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 75

Telsar Pharma Raises USD 14 Million In Series A Financing 77

Partnerships 78

Anaeropharma Science Enters into Research Agreement with Astellas Pharma 78

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 79

ClearPath Vaccines and Astellas Pharma Enter into Research Agreement with Boston Children's Hospital 80

Astellas Pharma, Institute of Medical Science, Chiba University and Asahi Kogyosha Enter into Research Agreement 81

Astellas Pharma Enters into Co-Promotion Agreement with MSD 82

Astellas Pharma Enters into Agreement with Medicines for Malaria Venture 83

Astellas Pharma Enters into Agreement with TB Alliance 84

Astellas Pharma and Toa Eiyo Enter into Co-Promotion Agreement 85

Astellas Pharma Amends Agreement with Pfizer 86

Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 87

Ribomic Enters into Research Agreement with Astellas Pharma 88

X-Chem Enters into Agreement with Astellas Pharma 89

Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 90

Astellas Pharma Enters into Research Agreement with GenomeDx Biosciences 91

Astellas Pharma Enters into Research Agreement with Quebec Urological Association Foundation 92

Courtagen Life Sciences Enters into Agreement with Astellas Pharma 93

IMSUT and Astellas Pharma Enter into Agreement 94

Excelra Knowledge Solutions Enters into Agreement with Astellas Pharma 95

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 96

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 98

Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma 99

Astellas Pharma Enters into Research Agreement with National Institute of Advanced Industrial Science and Technology 100

NuMedii Enters into Agreement with Astellas Pharma 101

Biovista Enters into Drug Collaboration Agreement with Astellas Pharma 102

Astellas Pharma Forms Joint Venture with ClearPath Development 103

Astellas Pharma Forms Joint Venture with Anokion 104

Cyclenium Pharma Enters into Discovery Agreement with Astellas Pharma 105

InVivoScribe Enters into Agreement with Astellas Pharma 106

Astellas Pharma Enters into R&D Agreement with Potenza Therapeutics 107

Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 108

Astellas Pharma Enters into Option Agreement with MD Anderson 109

Immuno-Biological Labs Enters Into Research Agreement With Astellas Pharma 110

ROVI Enters into Agreement with Astellas to Market Volutsa 111

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 112

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 113

Astellas Pharma Enters into Research Agreement with Harvard Medical School 114

Daewoong Pharma and Astellas Pharma Korea Enter into Agreement 115

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 116

Astellas Pharma Forms Joint Venture With ClearPath Development 117

Astellas Pharma Enters into Research Agreement with Immuno-Biological Labs 118

Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 119

Amgen and Astellas Pharma Form Joint Venture 120

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 121

Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 122

Astellas Pharma US Enters Into Distribution Agreement With Tecnofarma For Enzalutamide 123

Amgen Enters Into Co-Development Agreement With Astellas 124

Astellas Pharma Enters Into Co-Development Agreement With Ambrx 125

University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 126

Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 127

Astellas Pharma Enters Into Drug Discovery Agreement With AIST 128

KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases 129

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 130

Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma 131

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 132

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 134

Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine 135

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 136

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 137

Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho 139

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 140

Licensing Agreements 142

Astellas Pharma to Enter into Option Agreement with Gene Therapy Research Institution 142

Astellas Pharma Enters into Licensing Agreement with Aquinox Pharma 143

Cardurion Pharma Enters into Licensing Agreement with Astellas Pharma 144

Astellas Pharma Enters into Licensing Agreement with Tottori University 145

Astellas Institute for Regenerative Medicine Enters into Licensing Agreement with Universal Cells 146

BlueRock Therapeutics Enters into Licensing Agreement with Universal Cells 147

Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 148

Astellas Pharma Enters into Licensing Agreement with Affinivax 149

Astellas Pharma Enters into Licensing Agreement with Auration Biotech 150

Maruho Enters into Licensing Agreement with Astellas Pharma 151

Bellicum Pharma Enters into Licensing Agreement with Agensys 152

Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 153

Astellas Pharma Enters into Licensing Agreement with Chromocell 154

Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 155

Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 157

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 158

Euroscreen Enters into Licensing Agreement with Merck 159

EMERpharma Enters into Option Agreement with Astellas Pharma to License ASP2905 160

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 161

Astellas Pharma Expands Licensing Agreement with Cytokinetics 163

Astellas Pharma And Drais Pharma Enter Into Licensing Agreement To Develop ASP7035 165

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 166

Maruho Enters into Licensing Agreement with Astellas Pharma 168

Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin 169

Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 171

Astellas Pharma Enters into Licensing Agreement with Clino 172

Ocata Therapeutics Enters into Licensing Agreement with Allele Biotech 173

Agensys Enters into Licensing Agreement with Sea Lane Biotech 174

Equity Offering 175

Anokion to Raise USD16 Million in Private Placement of Shares 175

Cytokinetics Raises USD10 Million in Private Placement of Shares 176

Ocata Therapeutics Prices Public Offering of Shares and Warrants for USD30 Million 177

Advanced Cell to Raise USD30 Million in Private Placement of Shares 179

Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For USD 35 Million 180

Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For USD 1 Million 181

Asset Transactions 182

Astellas Pharma May Sell its Central and Eastern Europe Assets 182

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 183

LTL Pharma Acquires 16 Long-Listed Products in Japan from Astellas Pharma for USD182 Million 184

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 185

Thunderbolt Pharma Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma 186

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 187

MicroBiopharm Japan Acquires Kiyosu Plant from Astellas Pharma 188

Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 189

Cumberland Pharma Acquires Vaprisol From Astellas Pharma 190

Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 191

Seldar Pharma Acquires ASP7147 Compound From Astellas Pharma 192

Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma 193

Acquisition 194

Astellas Pharma Acquires Quethera 194

Astellas Pharma Acquires Universal Cells 195

Astellas Pharma Acquires Mitobridge 196

Astellas Pharma Acquires Ogeda for up to USD852 Million 197

Astellas Pharma Acquires Ganymed Pharma 198

Avara Pharma Acquires Astellas Pharma Technologies from Astellas US Holding 200

Astellas Pharma Acquires Ocata Therapeutics for up to USD384 Million in Tender Offer 201

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 203

GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For USD 99 Million 204

Astellas Pharma Inc - Key Competitors 206

Astellas Pharma Inc - Key Employees 207

Astellas Pharma Inc - Locations And Subsidiaries 210

Head Office 210

Other Locations & Subsidiaries 210

Joint Venture 216

Recent Developments 217

Strategy And Business Planning 217

Nov 20, 2018: Astellas Global Health Foundation launches - Foundation to support improving access to health for underserved populations 217

Oct 31, 2018: Astellas announces construction of new research, development and manufacturing facilities for drugs using innovative modalities/technologies including antibodies and cell therapies 218

Financial Announcements 219

Oct 31, 2018: Astellas announce financial results of for the first six months of FY2018 219

Apr 26, 2018: Astellas Reports Financial Results for FY2017 223

Jan 31, 2018: Astellas Reports Financial Results for the First Nine Months of FY2017 225

Oct 31, 2017: Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year Outlook 227

Jul 28, 2017: Astellas Reports First Quarter FY2017 Financial Results 229

Apr 27, 2017: Astellas Reports Full Year FY2016 Financial Results 231

Jan 31, 2017: Astellas Reports the First Nine Months Financial Results of FY2016 233

Corporate Communications 234

Nov 12, 2018: Astellas names Eloiza Domingo-Snyder to Head of Diversity and Inclusion 234

Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 235

Aug 23, 2018: Astellas announces promotion of Rodrigo Fernandez to Vice President, Latin America 236

May 15, 2018: Astellas Names Bernhardt Zeiher As New Chief Medical Officer 237

Mar 15, 2018: Astellas Names Percival Barretto-Ko President, Americas Operations 238

Mar 13, 2018: Astellas Announces Key Leadership Changes in Legal, Human Resources 239

Jan 31, 2018: Astellas Appoints Kenji Yasukawa as President and CEO 240

Jun 20, 2017: The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants 241

Apr 28, 2017: Astellas Announces Key Leadership Promotions in Development Organization 242

Feb 08, 2017: Astellas Announces Changes in Management Structure and Global Function 243

Feb 08, 2017: Astellas Announces Personnel Changes and Organizational Changes 244

Government and Public Interest 246

May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 246

Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 247

Nov 23, 2017: Innovative Medicines Canada and Astellas Announce Grant to the University Health Network's Transplant Innovation Fund 248

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 249

Jul 05, 2017: Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year 252

Jun 05, 2017: Kyoto University and Astellas Inaugurate "Alliance Station" with Aim of Realizing Advanced Medical Treatments 253

May 23, 2017: Action On Fistula To Transform 4,500 Lives By 2020 254

Jan 18, 2017: Astellas Announces Participation in Access Accelerated Builds on Company Commitment to improve Access to Health 256

Product News 257

Oct 31, 2017: Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs 257

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 258

Feb 02, 2018: The Breast Cancer Research Foundation Announces the Expansion of the Drug Research Collaborative to Better Understand Potential Treatment Pathways for Breast Cancer Patients 259

Clinical Trials 260

Aug 31, 2017: Astellas to Present New Data for IMAB362 at 2017 European Society of Medical Oncology Annual Meeting 260

Other Significant Developments 261

Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company's americas 2017 corporate social responsibility report card 261

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 262

Feb 05, 2018: Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees 263

Feb 05, 2018: Astellas Announces Organizational Changes 264

Jul 26, 2017: Astellas Announces Wind-Down of Agensys Research Operations 265

May 31, 2017: Astellas Announces New Global Website Launch 266

Appendix 267

Methodology 267

About GlobalData 267

Contact Us 267

Disclaimer 267


List Of Figure

List of Figures

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17


List Of Table

List of Tables

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

Astellas Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

Astellas Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 15

Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

Coda Biotherapeutics Raises USD19 Million in Series A Financing 31

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 32

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 34

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 36

Oncorus Raises Additional USD4 Million in Series A Financing 38

Cleave Biosciences Raises USD37 Million in Series B Financing Round 39

Tizona Therapeutics Raises USD43 Million in Series B Financing 41

Tizona Therapeutics Secures USD27 Million in Series A Funding Round 43

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 44

Euroscreen Raises USD17.8 Million in Series B Financing Round 46

Quethera Raises Funds in Seed Financing Round 48

Ocata Therapeutics Secures USD6 Million from Silicon Valley Bank 49

Kanyos Bio Raises USD16 Million in Venture Financing 50

Potenza Therapeutics Raises USD38 Million in Series A Venture Financing 51

Crescendo Biologics Raises Funds through Venture Financing 52

Innocrin Pharma Raises Funds through Venture Financing 53

Viamet Pharma Raises USD60 Million in Series D Venture Financing 54

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 55

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 56

Crescendo Biologics Raises USD 28 Million In Series A Financing 58

Seldar Pharma Raises USD 13 Million In Venture Financing 60

Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 61

Universal Cells Raises USD0.06 Million in Venture Financing 62

Ganymed Pharma Raises USD 60.7 Million In Series E Financing 63

Mitokyne Raises USD 45 Million In Series A Financing 64

Effector Therapeutics Raises USD 45 Million In Series A Financing 65

Tacurion Pharma To Raise USD 15 Million In Venture Financing 67

Cleave Biosciences Raises USD 54 Million In Series A Financing 68

DecImmune Therapeutics Raises USD 2.2 Million In Financing Round 70

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 71

Euroscreen Raises USD 13 Million In Series A Financing 73

F2G Raises USD 30 Million In Venture Financing 74

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 75

Telsar Pharma Raises USD 14 Million In Series A Financing 77

Anaeropharma Science Enters into Research Agreement with Astellas Pharma 78

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 79

ClearPath Vaccines and Astellas Pharma Enter into Research Agreement with Boston Children's Hospital 80

Astellas Pharma, Institute of Medical Science, Chiba University and Asahi Kogyosha Enter into Research Agreement 81

Astellas Pharma Enters into Co-Promotion Agreement with MSD 82

Astellas Pharma Enters into Agreement with Medicines for Malaria Venture 83

Astellas Pharma Enters into Agreement with TB Alliance 84

Astellas Pharma and Toa Eiyo Enter into Co-Promotion Agreement 85

Astellas Pharma Amends Agreement with Pfizer 86

Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 87

Ribomic Enters into Research Agreement with Astellas Pharma 88

X-Chem Enters into Agreement with Astellas Pharma 89

Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 90

Astellas Pharma Enters into Research Agreement with GenomeDx Biosciences 91

Astellas Pharma Enters into Research Agreement with Quebec Urological Association Foundation 92

Courtagen Life Sciences Enters into Agreement with Astellas Pharma 93

IMSUT and Astellas Pharma Enter into Agreement 94

Excelra Knowledge Solutions Enters into Agreement with Astellas Pharma 95

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 96

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 98

Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma 99

Astellas Pharma Enters into Research Agreement with National Institute of Advanced Industrial Science and Technology 100

NuMedii Enters into Agreement with Astellas Pharma 101

Biovista Enters into Drug Collaboration Agreement with Astellas Pharma 102

Astellas Pharma Forms Joint Venture with ClearPath Development 103

Astellas Pharma Forms Joint Venture with Anokion 104

Cyclenium Pharma Enters into Discovery Agreement with Astellas Pharma 105

InVivoScribe Enters into Agreement with Astellas Pharma 106

Astellas Pharma Enters into R&D Agreement with Potenza Therapeutics 107

Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 108

Astellas Pharma Enters into Option Agreement with MD Anderson 109

Immuno-Biological Labs Enters Into Research Agreement With Astellas Pharma 110

ROVI Enters into Agreement with Astellas to Market Volutsa 111

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 112

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 113

Astellas Pharma Enters into Research Agreement with Harvard Medical School 114

Daewoong Pharma and Astellas Pharma Korea Enter into Agreement 115

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 116

Astellas Pharma Forms Joint Venture With ClearPath Development 117

Astellas Pharma Enters into Research Agreement with Immuno-Biological Labs 118

Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 119

Amgen and Astellas Pharma Form Joint Venture 120

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 121

Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 122

Astellas Pharma US Enters Into Distribution Agreement With Tecnofarma For Enzalutamide 123

Amgen Enters Into Co-Development Agreement With Astellas 124

Astellas Pharma Enters Into Co-Development Agreement With Ambrx 125

University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 126

Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 127

Astellas Pharma Enters Into Drug Discovery Agreement With AIST 128

KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases 129

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 130

Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma 131

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 132

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 134

Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine 135

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 136

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 137

Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho 139

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 140

Astellas Pharma to Enter into Option Agreement with Gene Therapy Research Institution 142

Astellas Pharma Enters into Licensing Agreement with Aquinox Pharma 143

Cardurion Pharma Enters into Licensing Agreement with Astellas Pharma 144

Astellas Pharma Enters into Licensing Agreement with Tottori University 145

Astellas Institute for Regenerative Medicine Enters into Licensing Agreement with Universal Cells 146

BlueRock Therapeutics Enters into Licensing Agreement with Universal Cells 147

Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 148

Astellas Pharma Enters into Licensing Agreement with Affinivax 149

Astellas Pharma Enters into Licensing Agreement with Auration Biotech 150

Maruho Enters into Licensing Agreement with Astellas Pharma 151

Bellicum Pharma Enters into Licensing Agreement with Agensys 152

Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 153

Astellas Pharma Enters into Licensing Agreement with Chromocell 154

Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 155

Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 157

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 158

Euroscreen Enters into Licensing Agreement with Merck 159

EMERpharma Enters into Option Agreement with Astellas Pharma to License ASP2905 160

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 161

Astellas Pharma Expands Licensing Agreement with Cytokinetics 163

Astellas Pharma And Drais Pharma Enter Into Licensing Agreement To Develop ASP7035 165

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 166

Maruho Enters into Licensing Agreement with Astellas Pharma 168

Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin 169

Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 171

Astellas Pharma Enters into Licensing Agreement with Clino 172

Ocata Therapeutics Enters into Licensing Agreement with Allele Biotech 173

Agensys Enters into Licensing Agreement with Sea Lane Biotech 174

Anokion to Raise USD16 Million in Private Placement of Shares 175

Cytokinetics Raises USD10 Million in Private Placement of Shares 176

Ocata Therapeutics Prices Public Offering of Shares and Warrants for USD30 Million 177

Advanced Cell to Raise USD30 Million in Private Placement of Shares 179

Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For USD 35 Million 180

Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For USD 1 Million 181

Astellas Pharma May Sell its Central and Eastern Europe Assets 182

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 183

LTL Pharma Acquires 16 Long-Listed Products in Japan from Astellas Pharma for USD182 Million 184

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 185

Thunderbolt Pharma Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma 186

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 187

MicroBiopharm Japan Acquires Kiyosu Plant from Astellas Pharma 188

Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 189

Cumberland Pharma Acquires Vaprisol From Astellas Pharma 190

Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 191

Seldar Pharma Acquires ASP7147 Compound From Astellas Pharma 192

Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma 193

Astellas Pharma Acquires Quethera 194

Astellas Pharma Acquires Universal Cells 195

Astellas Pharma Acquires Mitobridge 196

Astellas Pharma Acquires Ogeda for up to USD852 Million 197

Astellas Pharma Acquires Ganymed Pharma 198

Avara Pharma Acquires Astellas Pharma Technologies from Astellas US Holding 200

Astellas Pharma Acquires Ocata Therapeutics for up to USD384 Million in Tender Offer 201

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 203

GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For USD 99 Million 204

Astellas Pharma Inc, Key Competitors 206

Astellas Pharma Inc, Key Employees 207

Astellas Pharma Inc, Other Locations 210

Astellas Pharma Inc, Subsidiaries 210

Astellas Pharma Inc, Joint Venture 216

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Astellas Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Astellas Pharma Inc (Astellas) is a research based pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company's product portfolio comprises both marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, diseases and disorders of central nervous system (CNS), and metabolic diseases, immunodeficiency diseases, and transplantation. The company is investigating enfortumab vedotin in Phase 2 and Phase 3 clinical trials for the treatment of urothelial cancer; zolbetuximab in Phase 3 clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer; roxadustat in Phase 3 clinical studies for the treatment of patients with anemia associated with chronic kidney disease (CKD) in patients on dialysis and non-dialysis; fezolinetant in Phase 2a clinical trials for the treatment of menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and gilteritinib for the treatment of for acute myeloid leukemia (AML). It operates in the Americas; Europe; and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Astellas Pharma Inc (4503)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 11

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

Astellas Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 31

Venture Financing 31

Coda Biotherapeutics Raises USD19 Million in Series A Financing 31

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 32

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 34

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 36

Oncorus Raises Additional USD4 Million in Series A Financing 38

Cleave Biosciences Raises USD37 Million in Series B Financing Round 39

Tizona Therapeutics Raises USD43 Million in Series B Financing 41

Tizona Therapeutics Secures USD27 Million in Series A Funding Round 43

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 44

Euroscreen Raises USD17.8 Million in Series B Financing Round 46

Quethera Raises Funds in Seed Financing Round 48

Ocata Therapeutics Secures USD6 Million from Silicon Valley Bank 49

Kanyos Bio Raises USD16 Million in Venture Financing 50

Potenza Therapeutics Raises USD38 Million in Series A Venture Financing 51

Crescendo Biologics Raises Funds through Venture Financing 52

Innocrin Pharma Raises Funds through Venture Financing 53

Viamet Pharma Raises USD60 Million in Series D Venture Financing 54

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 55

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 56

Crescendo Biologics Raises USD 28 Million In Series A Financing 58

Seldar Pharma Raises USD 13 Million In Venture Financing 60

Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 61

Universal Cells Raises USD0.06 Million in Venture Financing 62

Ganymed Pharma Raises USD 60.7 Million In Series E Financing 63

Mitokyne Raises USD 45 Million In Series A Financing 64

Effector Therapeutics Raises USD 45 Million In Series A Financing 65

Tacurion Pharma To Raise USD 15 Million In Venture Financing 67

Cleave Biosciences Raises USD 54 Million In Series A Financing 68

DecImmune Therapeutics Raises USD 2.2 Million In Financing Round 70

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 71

Euroscreen Raises USD 13 Million In Series A Financing 73

F2G Raises USD 30 Million In Venture Financing 74

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 75

Telsar Pharma Raises USD 14 Million In Series A Financing 77

Partnerships 78

Anaeropharma Science Enters into Research Agreement with Astellas Pharma 78

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 79

ClearPath Vaccines and Astellas Pharma Enter into Research Agreement with Boston Children's Hospital 80

Astellas Pharma, Institute of Medical Science, Chiba University and Asahi Kogyosha Enter into Research Agreement 81

Astellas Pharma Enters into Co-Promotion Agreement with MSD 82

Astellas Pharma Enters into Agreement with Medicines for Malaria Venture 83

Astellas Pharma Enters into Agreement with TB Alliance 84

Astellas Pharma and Toa Eiyo Enter into Co-Promotion Agreement 85

Astellas Pharma Amends Agreement with Pfizer 86

Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 87

Ribomic Enters into Research Agreement with Astellas Pharma 88

X-Chem Enters into Agreement with Astellas Pharma 89

Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 90

Astellas Pharma Enters into Research Agreement with GenomeDx Biosciences 91

Astellas Pharma Enters into Research Agreement with Quebec Urological Association Foundation 92

Courtagen Life Sciences Enters into Agreement with Astellas Pharma 93

IMSUT and Astellas Pharma Enter into Agreement 94

Excelra Knowledge Solutions Enters into Agreement with Astellas Pharma 95

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 96

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 98

Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma 99

Astellas Pharma Enters into Research Agreement with National Institute of Advanced Industrial Science and Technology 100

NuMedii Enters into Agreement with Astellas Pharma 101

Biovista Enters into Drug Collaboration Agreement with Astellas Pharma 102

Astellas Pharma Forms Joint Venture with ClearPath Development 103

Astellas Pharma Forms Joint Venture with Anokion 104

Cyclenium Pharma Enters into Discovery Agreement with Astellas Pharma 105

InVivoScribe Enters into Agreement with Astellas Pharma 106

Astellas Pharma Enters into R&D Agreement with Potenza Therapeutics 107

Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 108

Astellas Pharma Enters into Option Agreement with MD Anderson 109

Immuno-Biological Labs Enters Into Research Agreement With Astellas Pharma 110

ROVI Enters into Agreement with Astellas to Market Volutsa 111

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 112

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 113

Astellas Pharma Enters into Research Agreement with Harvard Medical School 114

Daewoong Pharma and Astellas Pharma Korea Enter into Agreement 115

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 116

Astellas Pharma Forms Joint Venture With ClearPath Development 117

Astellas Pharma Enters into Research Agreement with Immuno-Biological Labs 118

Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 119

Amgen and Astellas Pharma Form Joint Venture 120

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 121

Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 122

Astellas Pharma US Enters Into Distribution Agreement With Tecnofarma For Enzalutamide 123

Amgen Enters Into Co-Development Agreement With Astellas 124

Astellas Pharma Enters Into Co-Development Agreement With Ambrx 125

University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 126

Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 127

Astellas Pharma Enters Into Drug Discovery Agreement With AIST 128

KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases 129

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 130

Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma 131

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 132

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 134

Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine 135

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 136

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 137

Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho 139

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 140

Licensing Agreements 142

Astellas Pharma to Enter into Option Agreement with Gene Therapy Research Institution 142

Astellas Pharma Enters into Licensing Agreement with Aquinox Pharma 143

Cardurion Pharma Enters into Licensing Agreement with Astellas Pharma 144

Astellas Pharma Enters into Licensing Agreement with Tottori University 145

Astellas Institute for Regenerative Medicine Enters into Licensing Agreement with Universal Cells 146

BlueRock Therapeutics Enters into Licensing Agreement with Universal Cells 147

Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 148

Astellas Pharma Enters into Licensing Agreement with Affinivax 149

Astellas Pharma Enters into Licensing Agreement with Auration Biotech 150

Maruho Enters into Licensing Agreement with Astellas Pharma 151

Bellicum Pharma Enters into Licensing Agreement with Agensys 152

Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 153

Astellas Pharma Enters into Licensing Agreement with Chromocell 154

Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 155

Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 157

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 158

Euroscreen Enters into Licensing Agreement with Merck 159

EMERpharma Enters into Option Agreement with Astellas Pharma to License ASP2905 160

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 161

Astellas Pharma Expands Licensing Agreement with Cytokinetics 163

Astellas Pharma And Drais Pharma Enter Into Licensing Agreement To Develop ASP7035 165

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 166

Maruho Enters into Licensing Agreement with Astellas Pharma 168

Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin 169

Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 171

Astellas Pharma Enters into Licensing Agreement with Clino 172

Ocata Therapeutics Enters into Licensing Agreement with Allele Biotech 173

Agensys Enters into Licensing Agreement with Sea Lane Biotech 174

Equity Offering 175

Anokion to Raise USD16 Million in Private Placement of Shares 175

Cytokinetics Raises USD10 Million in Private Placement of Shares 176

Ocata Therapeutics Prices Public Offering of Shares and Warrants for USD30 Million 177

Advanced Cell to Raise USD30 Million in Private Placement of Shares 179

Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For USD 35 Million 180

Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For USD 1 Million 181

Asset Transactions 182

Astellas Pharma May Sell its Central and Eastern Europe Assets 182

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 183

LTL Pharma Acquires 16 Long-Listed Products in Japan from Astellas Pharma for USD182 Million 184

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 185

Thunderbolt Pharma Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma 186

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 187

MicroBiopharm Japan Acquires Kiyosu Plant from Astellas Pharma 188

Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 189

Cumberland Pharma Acquires Vaprisol From Astellas Pharma 190

Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 191

Seldar Pharma Acquires ASP7147 Compound From Astellas Pharma 192

Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma 193

Acquisition 194

Astellas Pharma Acquires Quethera 194

Astellas Pharma Acquires Universal Cells 195

Astellas Pharma Acquires Mitobridge 196

Astellas Pharma Acquires Ogeda for up to USD852 Million 197

Astellas Pharma Acquires Ganymed Pharma 198

Avara Pharma Acquires Astellas Pharma Technologies from Astellas US Holding 200

Astellas Pharma Acquires Ocata Therapeutics for up to USD384 Million in Tender Offer 201

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 203

GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For USD 99 Million 204

Astellas Pharma Inc - Key Competitors 206

Astellas Pharma Inc - Key Employees 207

Astellas Pharma Inc - Locations And Subsidiaries 210

Head Office 210

Other Locations & Subsidiaries 210

Joint Venture 216

Recent Developments 217

Strategy And Business Planning 217

Nov 20, 2018: Astellas Global Health Foundation launches - Foundation to support improving access to health for underserved populations 217

Oct 31, 2018: Astellas announces construction of new research, development and manufacturing facilities for drugs using innovative modalities/technologies including antibodies and cell therapies 218

Financial Announcements 219

Oct 31, 2018: Astellas announce financial results of for the first six months of FY2018 219

Apr 26, 2018: Astellas Reports Financial Results for FY2017 223

Jan 31, 2018: Astellas Reports Financial Results for the First Nine Months of FY2017 225

Oct 31, 2017: Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year Outlook 227

Jul 28, 2017: Astellas Reports First Quarter FY2017 Financial Results 229

Apr 27, 2017: Astellas Reports Full Year FY2016 Financial Results 231

Jan 31, 2017: Astellas Reports the First Nine Months Financial Results of FY2016 233

Corporate Communications 234

Nov 12, 2018: Astellas names Eloiza Domingo-Snyder to Head of Diversity and Inclusion 234

Sep 18, 2018: Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US 235

Aug 23, 2018: Astellas announces promotion of Rodrigo Fernandez to Vice President, Latin America 236

May 15, 2018: Astellas Names Bernhardt Zeiher As New Chief Medical Officer 237

Mar 15, 2018: Astellas Names Percival Barretto-Ko President, Americas Operations 238

Mar 13, 2018: Astellas Announces Key Leadership Changes in Legal, Human Resources 239

Jan 31, 2018: Astellas Appoints Kenji Yasukawa as President and CEO 240

Jun 20, 2017: The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants 241

Apr 28, 2017: Astellas Announces Key Leadership Promotions in Development Organization 242

Feb 08, 2017: Astellas Announces Changes in Management Structure and Global Function 243

Feb 08, 2017: Astellas Announces Personnel Changes and Organizational Changes 244

Government and Public Interest 246

May 31, 2018: Astellas Oncology C3 Prize Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World 246

Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 247

Nov 23, 2017: Innovative Medicines Canada and Astellas Announce Grant to the University Health Network's Transplant Innovation Fund 248

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 249

Jul 05, 2017: Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year 252

Jun 05, 2017: Kyoto University and Astellas Inaugurate "Alliance Station" with Aim of Realizing Advanced Medical Treatments 253

May 23, 2017: Action On Fistula To Transform 4,500 Lives By 2020 254

Jan 18, 2017: Astellas Announces Participation in Access Accelerated Builds on Company Commitment to improve Access to Health 256

Product News 257

Oct 31, 2017: Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs 257

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 258

Feb 02, 2018: The Breast Cancer Research Foundation Announces the Expansion of the Drug Research Collaborative to Better Understand Potential Treatment Pathways for Breast Cancer Patients 259

Clinical Trials 260

Aug 31, 2017: Astellas to Present New Data for IMAB362 at 2017 European Society of Medical Oncology Annual Meeting 260

Other Significant Developments 261

Oct 09, 2018: Astellas details progress and commitment to patients and the community in the company's americas 2017 corporate social responsibility report card 261

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 262

Feb 05, 2018: Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees 263

Feb 05, 2018: Astellas Announces Organizational Changes 264

Jul 26, 2017: Astellas Announces Wind-Down of Agensys Research Operations 265

May 31, 2017: Astellas Announces New Global Website Launch 266

Appendix 267

Methodology 267

About GlobalData 267

Contact Us 267

Disclaimer 267


List Of Figure

List of Figures

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15

Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17


List Of Table

List of Tables

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12

Astellas Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14

Astellas Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 15

Astellas Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 17

Astellas Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18

Coda Biotherapeutics Raises USD19 Million in Series A Financing 31

Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 32

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 34

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 36

Oncorus Raises Additional USD4 Million in Series A Financing 38

Cleave Biosciences Raises USD37 Million in Series B Financing Round 39

Tizona Therapeutics Raises USD43 Million in Series B Financing 41

Tizona Therapeutics Secures USD27 Million in Series A Funding Round 43

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 44

Euroscreen Raises USD17.8 Million in Series B Financing Round 46

Quethera Raises Funds in Seed Financing Round 48

Ocata Therapeutics Secures USD6 Million from Silicon Valley Bank 49

Kanyos Bio Raises USD16 Million in Venture Financing 50

Potenza Therapeutics Raises USD38 Million in Series A Venture Financing 51

Crescendo Biologics Raises Funds through Venture Financing 52

Innocrin Pharma Raises Funds through Venture Financing 53

Viamet Pharma Raises USD60 Million in Series D Venture Financing 54

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 55

Raze Therapeutics Raises USD24 Million in Series A Venture Financing 56

Crescendo Biologics Raises USD 28 Million In Series A Financing 58

Seldar Pharma Raises USD 13 Million In Venture Financing 60

Ganymed Pharmaceuticals Secures USD60.74 Million in Venture Funding 61

Universal Cells Raises USD0.06 Million in Venture Financing 62

Ganymed Pharma Raises USD 60.7 Million In Series E Financing 63

Mitokyne Raises USD 45 Million In Series A Financing 64

Effector Therapeutics Raises USD 45 Million In Series A Financing 65

Tacurion Pharma To Raise USD 15 Million In Venture Financing 67

Cleave Biosciences Raises USD 54 Million In Series A Financing 68

DecImmune Therapeutics Raises USD 2.2 Million In Financing Round 70

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 71

Euroscreen Raises USD 13 Million In Series A Financing 73

F2G Raises USD 30 Million In Venture Financing 74

PhaseBio Pharma Raises Additional USD 23 Million In The Third Tranche Of Series B Financing Round 75

Telsar Pharma Raises USD 14 Million In Series A Financing 77

Anaeropharma Science Enters into Research Agreement with Astellas Pharma 78

Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 79

ClearPath Vaccines and Astellas Pharma Enter into Research Agreement with Boston Children's Hospital 80

Astellas Pharma, Institute of Medical Science, Chiba University and Asahi Kogyosha Enter into Research Agreement 81

Astellas Pharma Enters into Co-Promotion Agreement with MSD 82

Astellas Pharma Enters into Agreement with Medicines for Malaria Venture 83

Astellas Pharma Enters into Agreement with TB Alliance 84

Astellas Pharma and Toa Eiyo Enter into Co-Promotion Agreement 85

Astellas Pharma Amends Agreement with Pfizer 86

Astellas Pharma Enters into Agreement with Institute of Medical Science, the University of Tokyo 87

Ribomic Enters into Research Agreement with Astellas Pharma 88

X-Chem Enters into Agreement with Astellas Pharma 89

Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 90

Astellas Pharma Enters into Research Agreement with GenomeDx Biosciences 91

Astellas Pharma Enters into Research Agreement with Quebec Urological Association Foundation 92

Courtagen Life Sciences Enters into Agreement with Astellas Pharma 93

IMSUT and Astellas Pharma Enter into Agreement 94

Excelra Knowledge Solutions Enters into Agreement with Astellas Pharma 95

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 96

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 98

Transplant Genomics Enters into Clinical Trial Agreement with Astellas Pharma 99

Astellas Pharma Enters into Research Agreement with National Institute of Advanced Industrial Science and Technology 100

NuMedii Enters into Agreement with Astellas Pharma 101

Biovista Enters into Drug Collaboration Agreement with Astellas Pharma 102

Astellas Pharma Forms Joint Venture with ClearPath Development 103

Astellas Pharma Forms Joint Venture with Anokion 104

Cyclenium Pharma Enters into Discovery Agreement with Astellas Pharma 105

InVivoScribe Enters into Agreement with Astellas Pharma 106

Astellas Pharma Enters into R&D Agreement with Potenza Therapeutics 107

Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 108

Astellas Pharma Enters into Option Agreement with MD Anderson 109

Immuno-Biological Labs Enters Into Research Agreement With Astellas Pharma 110

ROVI Enters into Agreement with Astellas to Market Volutsa 111

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 112

Dana-Farber Cancer Institute Enters into Research Agreement with Astellas Pharma 113

Astellas Pharma Enters into Research Agreement with Harvard Medical School 114

Daewoong Pharma and Astellas Pharma Korea Enter into Agreement 115

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 116

Astellas Pharma Forms Joint Venture With ClearPath Development 117

Astellas Pharma Enters into Research Agreement with Immuno-Biological Labs 118

Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 119

Amgen and Astellas Pharma Form Joint Venture 120

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 121

Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 122

Astellas Pharma US Enters Into Distribution Agreement With Tecnofarma For Enzalutamide 123

Amgen Enters Into Co-Development Agreement With Astellas 124

Astellas Pharma Enters Into Co-Development Agreement With Ambrx 125

University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 126

Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs 127

Astellas Pharma Enters Into Drug Discovery Agreement With AIST 128

KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases 129

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 130

Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma 131

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 132

Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 134

Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine 135

Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 136

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 137

Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho 139

Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 140

Astellas Pharma to Enter into Option Agreement with Gene Therapy Research Institution 142

Astellas Pharma Enters into Licensing Agreement with Aquinox Pharma 143

Cardurion Pharma Enters into Licensing Agreement with Astellas Pharma 144

Astellas Pharma Enters into Licensing Agreement with Tottori University 145

Astellas Institute for Regenerative Medicine Enters into Licensing Agreement with Universal Cells 146

BlueRock Therapeutics Enters into Licensing Agreement with Universal Cells 147

Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 148

Astellas Pharma Enters into Licensing Agreement with Affinivax 149

Astellas Pharma Enters into Licensing Agreement with Auration Biotech 150

Maruho Enters into Licensing Agreement with Astellas Pharma 151

Bellicum Pharma Enters into Licensing Agreement with Agensys 152

Adaptimmune Therapeutics Enters into Licensing Agreement with Universal Cells 153

Astellas Pharma Enters into Licensing Agreement with Chromocell 154

Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 155

Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 157

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 158

Euroscreen Enters into Licensing Agreement with Merck 159

EMERpharma Enters into Option Agreement with Astellas Pharma to License ASP2905 160

Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 161

Astellas Pharma Expands Licensing Agreement with Cytokinetics 163

Astellas Pharma And Drais Pharma Enter Into Licensing Agreement To Develop ASP7035 165

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 166

Maruho Enters into Licensing Agreement with Astellas Pharma 168

Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin 169

Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 171

Astellas Pharma Enters into Licensing Agreement with Clino 172

Ocata Therapeutics Enters into Licensing Agreement with Allele Biotech 173

Agensys Enters into Licensing Agreement with Sea Lane Biotech 174

Anokion to Raise USD16 Million in Private Placement of Shares 175

Cytokinetics Raises USD10 Million in Private Placement of Shares 176

Ocata Therapeutics Prices Public Offering of Shares and Warrants for USD30 Million 177

Advanced Cell to Raise USD30 Million in Private Placement of Shares 179

Advanced Cell Technology Files Registration Statement For Public Offering Of Securities For USD 35 Million 180

Advanced Cell Technology Completes First Tranche Of Private Placement Of Shares For USD 1 Million 181

Astellas Pharma May Sell its Central and Eastern Europe Assets 182

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 183

LTL Pharma Acquires 16 Long-Listed Products in Japan from Astellas Pharma for USD182 Million 184

Grunenthal to Acquire Qutenza from Astellas Pharma Europe 185

Thunderbolt Pharma Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma 186

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 187

MicroBiopharm Japan Acquires Kiyosu Plant from Astellas Pharma 188

Nichi-Iko Pharma Acquires Pharmaceutical Manufacturing Business from Astellas Pharma Tech 189

Cumberland Pharma Acquires Vaprisol From Astellas Pharma 190

Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 191

Seldar Pharma Acquires ASP7147 Compound From Astellas Pharma 192

Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma 193

Astellas Pharma Acquires Quethera 194

Astellas Pharma Acquires Universal Cells 195

Astellas Pharma Acquires Mitobridge 196

Astellas Pharma Acquires Ogeda for up to USD852 Million 197

Astellas Pharma Acquires Ganymed Pharma 198

Avara Pharma Acquires Astellas Pharma Technologies from Astellas US Holding 200

Astellas Pharma Acquires Ocata Therapeutics for up to USD384 Million in Tender Offer 201

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 203

GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For USD 99 Million 204

Astellas Pharma Inc, Key Competitors 206

Astellas Pharma Inc, Key Employees 207

Astellas Pharma Inc, Other Locations 210

Astellas Pharma Inc, Subsidiaries 210

Astellas Pharma Inc, Joint Venture 216

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Astellas Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.